PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
Luis Paz‐Ares(Hospital Universitario Virgen del Rocío), Filippo de Marinis(Carlo Forlanini Hospital), Mircea Dediu(Institutul Oncologic Bucuresti), Michael Thomas(Heidelberg University), Jean-Louis Pujol(Université de Montpellier), Paolo Bidoli(Azienda Ospedaliera San Gerardo), O. Molinier(Centre Hospitalier du Mans), Tarini Prasad Sahoo(Jawaharlal Nehru Cancer Hospital and Research Centre), Eckart Laack(Amedes MVZ Hamburg), Martin Reck(LungenClinic Grosshansdorf), Jesus Corral Jaime(Hospital Universitario Virgen del Rocío), Symantha Melemed(Eli Lilly (United States)), William J. John(Eli Lilly (United States)), Nadia Chouaki, Annamaria H. Zimmermann(Eli Lilly (United States)), Carla Visseren‐Grul(Eli Lilly (Netherlands)), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati)
Cited by 53
Abstract
LBA7507 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Related Papers
No related papers found
Powered by citation graph analysis